| Sep 28 |
3 Surprisingly Underrated Stocks to Buy Right Now
|
| Sep 28 |
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
|
| Sep 27 |
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
|
| Sep 27 |
Bristol Cobenfy approval draws optimism from Street, though with caveats
|
| Sep 27 |
Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns
|
| Sep 27 |
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
|
| Sep 27 |
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
|
| Sep 27 |
FDA approves new Bristol Myers Squibb schizophrenia drug
|
| Sep 27 |
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
|
| Sep 27 |
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
|
